Synmosa Biopharma (ROCO:4114) Cyclically Adjusted Revenue per Share: NT$9.31 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4114 Synmosa Biopharma Corp ROCO:4114
83 GF Score
Price NT$30.05
GF Value NT$32.26
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Synmosa Biopharma Cyclically Adjusted Revenue per Share?

Synmosa Biopharma ROCO:4114 +1.86% 83 Cyclically Adjusted Revenue per Share is NT$9.31 as of Mar. 2026. GuruFocus rates ROCO:4114 with a GF Score™ of 83/100 and a GF Value™ of NT$32.26 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Synmosa Biopharma's adjusted revenue per share for the three months ended in Mar. 2026 was NT$3.002. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$9.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Synmosa Biopharma's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Synmosa Biopharma was 13.10% per year. The lowest was 9.80% per year. And the median was 12.20% per year.

As of today (2026-08-12), Synmosa Biopharma's current stock price is NT$30.05. Synmosa Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$9.31. Synmosa Biopharma's Cyclically Adjusted PS Ratio of today is 3.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Synmosa Biopharma was 5.34. The lowest was 1.78. And the median was 3.31.


Synmosa Biopharma  (ROCO:4114) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Synmosa Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=30.05/9.31
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Synmosa Biopharma was 5.34. The lowest was 1.78. And the median was 3.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Synmosa Biopharma Cyclically Adjusted Revenue per Share Related Terms


Synmosa Biopharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Synmosa Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synmosa Biopharma Cyclically Adjusted Revenue per Share Chart

Synmosa Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.93 6.82 7.61 8.36 9.02

Synmosa Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.61 8.76 8.92 9.02 9.31

ROCO:4114 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Synmosa Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synmosa Biopharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synmosa Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Synmosa Biopharma's Cyclically Adjusted PS Ratio falls into.


ROCO:4114
83GF Score
Synmosa Biopharma Corp ROCO:4114
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Synmosa Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Synmosa Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.002/330.2130*330.2130
=3.002

Current CPI (Mar. 2026) = 330.2130.

Synmosa Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.555 241.018 2.130
201609 1.089 241.428 1.489
201612 1.050 241.432 1.436
201703 1.053 243.801 1.426
201706 1.233 244.955 1.662
201709 1.039 246.819 1.390
201712 1.326 246.524 1.776
201803 1.437 249.554 1.901
201806 1.177 251.989 1.542
201809 1.428 252.439 1.868
201812 1.465 251.233 1.926
201903 1.629 254.202 2.116
201906 1.680 256.143 2.166
201909 1.785 256.759 2.296
201912 1.797 256.974 2.309
202003 1.940 258.115 2.482
202006 1.669 257.797 2.138
202009 1.715 260.280 2.176
202012 1.888 260.474 2.393
202103 1.748 264.877 2.179
202106 1.625 271.696 1.975
202109 1.605 274.310 1.932
202112 1.928 278.802 2.284
202203 2.030 287.504 2.332
202206 2.258 296.311 2.516
202209 2.397 296.808 2.667
202212 2.690 296.797 2.993
202303 2.691 301.836 2.944
202306 3.049 305.109 3.300
202309 2.460 307.789 2.639
202312 2.652 306.746 2.855
202403 2.561 312.332 2.708
202406 2.440 314.175 2.565
202409 2.824 315.301 2.958
202412 3.014 315.605 3.154
202503 2.799 319.799 2.890
202506 2.677 322.561 2.741
202509 2.811 324.800 2.858
202512 2.950 324.054 3.006
202603 3.002 330.213 3.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$9.31 mean?
Synmosa Biopharma (ROCO:4114) has a Cyclically Adjusted Revenue per Share of NT$9.31 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Synmosa Biopharma and its competitors.
Is Synmosa Biopharma's Cyclically Adjusted Revenue per Share too high?
Synmosa Biopharma's current Cyclically Adjusted Revenue per Share is NT$9.31. Overall, Synmosa Biopharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Synmosa Biopharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Synmosa Biopharma's Cyclically Adjusted Revenue per Share of NT$9.31 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Synmosa Biopharma and its competitors. Synmosa Biopharma's current Cyclically Adjusted Revenue per Share is NT$9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synmosa Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Synmosa Biopharma (ROCO:4114) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.26, compared to a current price of NT$30.05 — trading 6.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$9.31. Synmosa Biopharma's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Synmosa Biopharma (ROCO:4114), the current Cyclically Adjusted Revenue per Share is NT$9.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Synmosa Biopharma (ROCO:4114) Overvalued in 2026?

Based on GuruFocus' analysis, Synmosa Biopharma stock appears to be undervalued. The current stock price of NT$30.05 is trading 6.9% below its estimated GF Value™ of NT$32.26. GuruFocus considers Synmosa Biopharma to be Fairly Valued.

Key valuation signals for ROCO:4114:

  • Cyclically Adjusted Revenue per Share: NT$9.31
  • GF Value™: NT$32.26 vs. price of NT$30.05 (6.9% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4114 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Synmosa Biopharma Business Description

Address No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN
Synmosa Biopharma Corp is engaged in pharmaceuticals and medical devices, cosmetics, animal drugs, chemical food additives, beverages manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. Its segments include the Active Pharmaceutical Ingredients segment and the Generic Drugs segment. The Generic Drugs segment derives the majority of the revenue.
83GF Score

Get the complete analysis for ROCO:4114

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.05
Price
NT$32.26
GF Value